Complete financial analysis of Tekla Life Sciences Investors (HQL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tekla Life Sciences Investors, a leading company in the Asset Management industry within the Financial Services sector.
You may be interested
- Alliance Integrated Metaliks Limited (AIML.BO) Income Statement Analysis – Financial Results
- Airthings ASA (ARTGF) Income Statement Analysis – Financial Results
- Wistron NeWeb Corporation (6285.TW) Income Statement Analysis – Financial Results
- Varonis Systems, Inc. (VRNS) Income Statement Analysis – Financial Results
- The Tochigi Bank, Ltd. (8550.T) Income Statement Analysis – Financial Results
Tekla Life Sciences Investors (HQL)
About Tekla Life Sciences Investors
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86.69M | 23.52M | -103.25M | 65.69M | 124.08M | -69.34M | 29.82M | 69.81M | 6.29M | 1.32M | 876.79K | 516.76K | 2.14M | 570.00K | 1.82M | 460.00K | 1.67M | 2.88M | 2.30M | 890.00K | 320.00K | 610.00K | 940.00K | 1.77M | 140.00K | 320.00K | 420.00K |
| Cost of Revenue | 0.00 | 5.24M | 5.55M | 6.08M | 5.21M | 5.00M | 4.77M | 4.61M | 4.95M | 5.65M | 4.14M | 3.10M | 2.48M | 3.02M | 2.99M | 2.85M | 3.76M | 3.62M | 2.93M | 2.81M | 2.78M | 2.44M | 2.86M | 3.26M | 1.64M | 1.63M | 1.60M |
| Gross Profit | 86.69M | 18.28M | -108.80M | 59.61M | 118.88M | -74.35M | 25.05M | 65.20M | 1.34M | -4.33M | -3.26M | -2.58M | -335.50K | -2.45M | -1.17M | -2.39M | -2.09M | -740.00K | -630.00K | -1.92M | -2.46M | -1.83M | -1.92M | -1.49M | -1.50M | -1.31M | -1.18M |
| Gross Profit Ratio | 100.00% | 77.71% | 105.37% | 90.75% | 95.80% | 107.22% | 84.00% | 93.40% | 21.34% | -327.02% | -372.18% | -499.89% | -15.64% | -429.82% | -64.29% | -519.57% | -125.15% | -25.69% | -27.39% | -215.73% | -768.75% | -300.00% | -204.26% | -84.18% | -1,071.43% | -409.38% | -280.95% |
| Research & Development | 0.00 | 0.00 | -3.28 | 1.43 | 3.15 | -1.84 | 0.80 | 1.46 | -1.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.33M | 903.14K | 1.08M | 844.02K | 751.32K | 876.76K | 880.76K | 991.51K | 5.23M | 6.04M | 4.64M | 3.69M | 3.43M | 1.15M | 630.00K | 590.00K | 680.00K | 720.00K | 550.00K | 510.00K | 530.00K | 450.00K | 470.00K | 340.00K | 230.00K | 190.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.33M | 903.14K | 1.08M | 844.02K | 751.32K | 876.76K | 880.76K | 991.51K | -1.89 | 6.04M | 4.64M | 3.69M | 3.43M | 1.15M | 630.00K | 590.00K | 680.00K | 720.00K | 550.00K | 510.00K | 530.00K | 450.00K | 470.00K | 340.00K | 230.00K | 190.00K | 0.00 |
| Other Expenses | 85.35M | 22.62M | 275.97K | 313.69K | 278.66K | 259.76K | 466.64K | 423.33K | 20.74M | 143.44K | 130.00K | 150.00K | 200.00K | 200.00K | 160.00K | 170.00K | 140.00K | 250.00K | 160.00K | 150.00K | 80.00K | 60.00K | 120.00K | 110.00K | 10.00K | 40.00K | 290.00K |
| Operating Expenses | 86.69M | 23.52M | 1.35M | 1.16M | 1.03M | 1.14M | 1.16M | 1.26M | 13.35M | 39.18M | 88.39M | 84.13M | 75.49M | 1.35M | 790.00K | 760.00K | 820.00K | 970.00K | 710.00K | 660.00K | 610.00K | 510.00K | 590.00K | 450.00K | 240.00K | 230.00K | 290.00K |
| Cost & Expenses | 86.69M | 23.52M | 1.35M | 1.16M | 1.03M | 1.14M | 5.59M | 5.56M | 1.34M | 39.18M | 88.39M | 84.13M | 75.49M | 4.37M | 3.78M | 3.61M | 4.58M | 4.59M | 3.64M | 3.47M | 3.39M | 2.95M | 3.45M | 3.71M | 1.88M | 1.86M | 1.89M |
| Interest Income | 1.04M | 204.45K | 50.09K | 0.00 | 164.80K | 216.70K | 90.71K | 90.56K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.27M | 72.43M | 45.22M | 93.03M | 87.82M | 78.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 0.00 | 27.60M | 2.99M | 4.14M | 2.11M | 2.88M | 3.61M | 3.88M | 3.79M | 4.72M | 3.77M | 3.17M | 1.28M | 41.27M | 12.15M | -18.52M | 63.17M | 52.22M | -20.10M | 47.35M | 10.23M | 40.96M | -47.89M | -93.09M | -28.63M | 16.72M | 23.28M |
| EBITDA | 0.00 | 22.35M | -104.61M | 64.54M | 123.06M | -70.47M | 28.67M | 68.56M | 0.00 | 0.00 | 0.00 | 0.00 | 78.91M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| EBITDA Ratio | 0.00% | 95.03% | 101.31% | 98.24% | 99.17% | 101.64% | 204.33% | 201.96% | 289.30% | 3,419.13% | 10,610.66% | 16,993.50% | 3,679.80% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| Operating Income | 0.00 | -5.24M | -104.60M | 64.53M | 123.05M | -70.48M | -3.61M | -3.88M | -3.79M | -4.72M | -3.77M | -3.17M | -1.28M | -3.80M | -1.96M | -3.15M | -2.92M | -1.71M | -1.34M | -2.59M | -3.07M | -2.34M | -2.52M | -1.94M | -1.75M | -1.53M | -1.47M |
| Operating Income Ratio | 0.00% | -22.29% | 101.31% | 98.24% | 99.17% | 101.64% | -12.10% | -5.56% | -60.25% | -357.04% | -429.50% | -613.43% | -59.85% | -666.67% | -107.69% | -684.78% | -174.85% | -59.38% | -58.26% | -291.01% | -959.38% | -383.61% | -268.09% | -109.60% | -1,250.00% | -478.13% | -350.00% |
| Total Other Income/Expenses | 85.30M | 27.60M | -101.61M | 6.08M | 5.21M | -67.60M | 32.61M | 72.74M | -8.12M | 45.22M | 93.03M | 87.82M | 78.91M | 41.27M | 12.15M | -18.52M | 63.17M | 52.22M | -20.10M | 47.35M | 10.23M | 40.96M | -47.89M | -93.09M | -28.63M | 16.72M | 23.28M |
| Income Before Tax | 85.30M | 22.35M | -104.60M | 64.53M | 123.05M | -70.48M | 28.66M | 68.56M | -11.91M | 40.50M | 89.27M | 84.65M | 77.63M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| Income Before Tax Ratio | 98.40% | 95.02% | 101.31% | 98.24% | 99.17% | 101.64% | 96.12% | 98.20% | -189.33% | 3,062.09% | 10,181.17% | 16,380.07% | 3,619.95% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| Income Tax Expense | 0.00 | 0.00 | -2.99M | -4.15M | -2.13M | -2.88M | 1.00 | 3.00 | 26.32M | 45.22M | 93.03M | 87.82M | 78.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 85.30M | 22.35M | -104.60M | 64.53M | 123.05M | -70.48M | 28.66M | 68.56M | -11.91M | 40.50M | 89.27M | 84.65M | 77.63M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| Net Income Ratio | 98.40% | 95.02% | 101.31% | 98.24% | 99.17% | 101.64% | 96.12% | 98.20% | -189.30% | 3,062.09% | 10,181.17% | 16,380.07% | 3,619.95% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| EPS | 0.00 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.28 | 3.21 | 1.00 | 2.06 | 4.70 | 5.65 | 5.38 | 2.57 | 0.47 | -0.99 | 2.86 | 2.52 | -1.11 | 3.55 | 0.59 | 3.38 | -4.84 | -10.20 | -4.17 | 2.17 | 3.26 |
| EPS Diluted | 0.00 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.23 | 3.21 | 20.74M | 2.06 | 4.70 | 5.64 | 5.38 | 2.57 | 0.47 | -0.99 | 2.86 | 2.52 | -1.11 | 3.55 | 0.59 | 3.38 | -4.84 | -10.20 | -4.17 | 2.17 | 3.26 |
| Weighted Avg Shares Out | 28.06M | 28.29M | 25.68M | 24.26M | 23.85M | 23.18M | 22.41M | 21.36M | -11.91M | 19.69M | 19.01M | 14.99M | 14.43M | 14.58M | 21.84M | 21.95M | 21.08M | 20.08M | 19.23M | 12.61M | 12.07M | 11.41M | 10.41M | 9.32M | 7.29M | 7.01M | 6.68M |
| Weighted Avg Shares Out (Dil) | 28.06M | 28.29M | 25.68M | 24.26M | 23.85M | 23.18M | 23.30M | 21.36M | -0.57 | 19.69M | 19.01M | 14.99M | 14.43M | 14.58M | 21.84M | 21.95M | 21.08M | 20.08M | 19.23M | 12.61M | 12.07M | 11.41M | 10.41M | 9.32M | 7.29M | 7.01M | 6.68M |
Tekla Life Sciences Investors (NYSE:HQL) Shares Sold by Bank of America Corp DE
Bank of America Corp DE cut its holdings in shares of Tekla Life Sciences Investors (NYSE:HQL) by 12.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor...
Tekla Life Sciences Investors (NYSE:HQL) Shares Sold by Ladenburg Thalmann Financial Services Inc.
Ladenburg Thalmann Financial Services Inc. trimmed its holdings in shares of Tekla Life Sciences Investors (NYSE:HQL) by 20.1% during the fourth quarter, Holdings Channel reports. The firm owned 49,430 shares of the company’s stock after selling 12,445 shares during the...
Guggenheim Capital LLC Acquires 7,370 Shares of Tekla Life Sciences Investors (NYSE:HQL)
Guggenheim Capital LLC raised its position in Tekla Life Sciences Investors (NYSE:HQL) by 44.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,055...
1832 Asset Management L.P. Purchases 45,934 Shares of Tekla Life Sciences Investors (NYSE:HQL)
1832 Asset Management L.P. boosted its position in Tekla Life Sciences Investors (NYSE:HQL) by 57.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 125,934 shares of the company’s stock after acquiring...
Tekla World Healthcare Fund Paid Distribution
On March 31, 2020, Tekla World Healthcare Fund paid a monthly distribution of $0.1167 per share. It is currently estimated that this distribution is derived from return of capital or other capital source. The composition of this and subsequent distributions...
Advisors Asset Management Inc. Buys 62,317 Shares of Tekla Life Sciences Investors (NYSE:HQL)
Advisors Asset Management Inc. grew its stake in Tekla Life Sciences Investors (NYSE:HQL) by 88.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 132,780 shares of...
Citigroup Inc. Buys 5,977 Shares of Tekla Life Sciences Investors (NYSE:HQL)
Citigroup Inc. lifted its stake in shares of Tekla Life Sciences Investors (NYSE:HQL) by 75.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,908 shares of...
Tekla Life Sciences Investors (NYSE:HQL) Shares Bought by Raymond James Financial Services Advisors Inc.
Raymond James Financial Services Advisors Inc. raised its holdings in Tekla Life Sciences Investors (NYSE:HQL) by 17.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,862 shares of...
Daniel R. Omstead Purchases 8,300 Shares of Tekla Life Sciences Investors (NYSE:HQL) Stock
Tekla Life Sciences Investors (NYSE:HQL) President Daniel R. Omstead bought 8,300 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were acquired at an average price of $13.27 per share, with a total value of...
Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program
Tekla Life Sciences Investors (the "Fund") announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its...
Source: https://incomestatements.info
Category: Stock Reports